Cordlife Group faces operational limits until January 2025

It expects a continued negative financial impact for 2024.

The Ministry of Health has given Cordlife Group Limited a directive which alters its cord-blood banking service license, as it resumes operations with restrictions following its suspension on 15 June.

Starting 15 September until 13 January 2025, Cordlife shall not collect, test, process, and store a maximum of 30 new cord blood units per month from infant donors, unless earlier approval is granted by the Director-General of Health, the company said in a bourse filing.

Due to the operational limits, the group expects a continued negative financial impact for the fiscal year ending 2024.

In August this year, Cordlife’s substantial shareholder, Nanjing Xinjiekou, withdrew its bid to acquire the group’s remaining shares.

Follow the link s for more news on

Cordlife Group

Ministry of Health

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia